Trial · NCT04076579
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate | Cohort 1 | 0 | Participants | ||
| Overall Response Rate | Cohort 2 | 2 | Participants | ||
| Progression Free Survival | Cohort 1 | 4.1 | 95% Confidence Interval 3.3 to NA | months | |
| Progression Free Survival | Cohort 2 | 3.8 | 95% Confidence Interval 2.2 to NA | months | |
| Progression Free Survival | Cohort 1 | 8.9 | percentage of patients | ||
| Progression Free Survival | Cohort 2 | 20.2 | percentage of patients | ||
| Overall Survival | Cohort 1 | 1 year post enrollment | 0.52 | 95% Confidence Interval 0.28 to 0.94 | probability estimates |
| Overall Survival | Cohort 2 | 1 year post enrollment | 0.48 | 95% Confidence Interval 0.24 to 0.94 | probability estimates |
| Overall Survival | Cohort 1 | 2 year post enrollment | 0 | 95% Confidence Interval 0 to 0 | probability estimates |
| Overall Survival | Cohort 2 | 2 year post enrollment | 0.12 | 95% Confidence Interval 0.02 to 0.74 | probability estimates |
| Incidence of Adverse Events | Cohort 1 | Acute Kidney Injury- Grade 3 | 0 | number of events | |
| Incidence of Adverse Events | Cohort 2 | Acute Kidney Injury- Grade 3 | 1 | number of events | |
| Incidence of Adverse Events | Cohort 1 | Alanine aminotransferase increased- Grade 3 | 1 | number of events | |
| Incidence of Adverse Events | Cohort 2 | Alanine aminotransferase increased- Grade 3 | 3 | number of events | |
| Incidence of Adverse Events | Cohort 1 | Anemia- Grade 3 | 5 | number of events | |
| Incidence of Adverse Events | Cohort 2 | Anemia- Grade 3 | 1 | number of events | |
| Incidence of Adverse Events | Cohort 1 | Aspartate aminotransferase increased - Grade 3 | 1 | number of events | |
| Incidence of Adverse Events | Cohort 2 | Aspartate aminotransferase increased - Grade 3 | 1 | number of events | |
| Incidence of Adverse Events | Cohort 1 | Blood bilirubin increased- Grade 3 | 1 | number of events | |
| Incidence of Adverse Events | Cohort 2 | Blood bilirubin increased- Grade 3 | 0 | number of events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04076579/results